azathioprine has been researched along with Renal Insufficiency, Chronic in 11 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
Renal Insufficiency, Chronic: Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Azathioprine (AZA) was added for remission-maintenance therapy." | 5.48 | Neutropenia related to an azathioprine metabolic disorder induced by an inosine triphosphate pyrophosphohydrolase (ITPA) gene mutation in a patient with PR3-ANCA-positive microscopic polyangiitis . ( Hasegawa, T; Honda, K; Ishizuka, S; Ito, S; Kobayashi, A; Komine, K; Kubota, T; Motoi, Y; Niikura, T; Saito, Z; Sasaki, T; Yamamoto, H; Yokoo, T, 2018) |
| " The aim of this study was to evaluate the outcome of a conversion from CNI-based immunosuppressive protocol to sirolimus (SRL) in recipients with graft in chronic kidney disease (CKD) grade III and proteinuria below 500 mg/day." | 3.79 | Conversion from calcineurin inhibitors to sirolimus of recipients with chronic kidney graft disease grade III for a period 2003-2011. ( Aleksić, P; Drasković-Pavlović, B; Dujić, A; Hrvacević, R; Ignjatović, L; Jovanović, D; Karan, Z; Kovacević, Z; Maksić, D; Rabrenović, V; Tomić, A; Vavić, N, 2013) |
| "Azathioprine (AZA) was added for remission-maintenance therapy." | 1.48 | Neutropenia related to an azathioprine metabolic disorder induced by an inosine triphosphate pyrophosphohydrolase (ITPA) gene mutation in a patient with PR3-ANCA-positive microscopic polyangiitis . ( Hasegawa, T; Honda, K; Ishizuka, S; Ito, S; Kobayashi, A; Komine, K; Kubota, T; Motoi, Y; Niikura, T; Saito, Z; Sasaki, T; Yamamoto, H; Yokoo, T, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Phanish, MK | 1 |
| Hull, RP | 1 |
| Andrews, PA | 1 |
| Popoola, J | 1 |
| Kingdon, EJ | 1 |
| MacPhee, IAM | 1 |
| Rasheed, N | 1 |
| Ahuja, R | 1 |
| Borneo, H | 1 |
| Tziastoudi, M | 1 |
| Pissas, G | 1 |
| Raptis, G | 1 |
| Cholevas, C | 1 |
| Eleftheriadis, T | 1 |
| Dounousi, E | 1 |
| Stefanidis, I | 1 |
| Theoharides, TC | 1 |
| Palamuthusingam, D | 1 |
| Mantha, M | 1 |
| Dheda, S | 1 |
| Honda, K | 1 |
| Kobayashi, A | 1 |
| Niikura, T | 1 |
| Hasegawa, T | 1 |
| Saito, Z | 1 |
| Ito, S | 1 |
| Sasaki, T | 1 |
| Komine, K | 1 |
| Ishizuka, S | 1 |
| Motoi, Y | 1 |
| Kubota, T | 1 |
| Yamamoto, H | 1 |
| Yokoo, T | 1 |
| Lopez-Lopez, I | 1 |
| Rodelo-Haad, C | 1 |
| Agüera, ML | 1 |
| Cabello-Jabalquinto, R | 1 |
| Esquivias-Motta, E | 1 |
| Navarro, MD | 1 |
| Aljama, P | 1 |
| Rodriguez-Benot, A | 1 |
| Ignjatović, L | 1 |
| Hrvacević, R | 1 |
| Jovanović, D | 1 |
| Kovacević, Z | 1 |
| Vavić, N | 1 |
| Rabrenović, V | 1 |
| Tomić, A | 1 |
| Aleksić, P | 1 |
| Drasković-Pavlović, B | 1 |
| Dujić, A | 1 |
| Karan, Z | 1 |
| Maksić, D | 1 |
| Jones, RB | 1 |
| Furuta, S | 1 |
| Tervaert, JW | 1 |
| Hauser, T | 1 |
| Luqmani, R | 1 |
| Morgan, MD | 1 |
| Peh, CA | 1 |
| Savage, CO | 1 |
| Segelmark, M | 1 |
| Tesar, V | 1 |
| van Paassen, P | 1 |
| Walsh, M | 1 |
| Westman, K | 1 |
| Jayne, DR | 1 |
| Parodis, I | 1 |
| Ding, H | 1 |
| Zickert, A | 1 |
| Arnaud, L | 1 |
| Larsson, A | 1 |
| Svenungsson, E | 1 |
| Mohan, C | 1 |
| Gunnarsson, I | 1 |
| Pham, PT | 1 |
| Pham, PC | 1 |
| Edwards, NL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis[NCT02626845] | Phase 4 | 3 participants (Actual) | Interventional | 2015-12-31 | Terminated (stopped due to Slow recruitment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for azathioprine and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
A Systematic Review and Meta-Analysis of Pharmacogenetic Studies in Patients with Chronic Kidney Disease.
Topics: Azathioprine; Cyclosporine; Humans; Pharmacogenomic Testing; Pharmacogenomic Variants; Polymorphism, | 2021 |
1 trial available for azathioprine and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Der | 2015 |
9 other studies available for azathioprine and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Immunological risk stratification and tailored minimisation of immunosuppression in renal transplant recipients.
Topics: Adult; Aged; Azathioprine; Basiliximab; Drug Administration Schedule; Female; Glucocorticoids; Graft | 2020 |
Polyangiitis overlap syndrome: a novel presentation of microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis.
Topics: Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Churg-Strauss Syndrome; Cyclophosphamide; Fema | 2021 |
HMG CoA reductase inhibitor associated myositis and autoimmune hepatitis.
Topics: Aged; Anti-Inflammatory Agents; Azathioprine; Diabetes Mellitus, Type 2; Fatal Outcome; Female; Hepa | 2017 |
Neutropenia related to an azathioprine metabolic disorder induced by an inosine triphosphate pyrophosphohydrolase (ITPA) gene mutation in a patient with PR3-ANCA-positive microscopic polyangiitis
.
Topics: Aged; Azathioprine; Humans; Male; Microscopic Polyangiitis; Mutation; Neutropenia; Pyrophosphatases; | 2018 |
Administration of mycophenolic acid is not associated with malformations in descendants from kidney transplanted males.
Topics: Adult; Azathioprine; Drug Therapy, Combination; Female; Fertilization; Graft Rejection; Humans; Immu | 2018 |
Conversion from calcineurin inhibitors to sirolimus of recipients with chronic kidney graft disease grade III for a period 2003-2011.
Topics: Adult; Azathioprine; Biomarkers; Calcineurin Inhibitors; Creatinine; Cytomegalovirus Infections; Fem | 2013 |
Serum soluble tumour necrosis factor receptor-2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Azathioprine; Biomarkers; Cohor | 2017 |
The impact of mycophenolate mofetil versus azathioprine as adjunctive therapy to cyclosporine on the rates of renal allograft loss due to glomerular disease recurrence.
Topics: Adolescent; Adult; Aged; Azathioprine; Cyclosporine; Female; Follow-Up Studies; Glomerular Filtratio | 2012 |
Case 9: initiation of urate-lowering therapy for advanced gout complicated by chronic renal insufficiency.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Contraindications; Drug Interact | 2006 |